Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 8,453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolism Disorder, Glucose Clear all
Completed Not applicable Interventional Results available

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

NCT00763412
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency
Interventions
placebo, repaglinide
Drug
Lead sponsor
Arbelaez, Ana Maria
Individual
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Nov 1, 2026, 1:21 AM EDT
Recruiting No phase listed Observational

ECHO Diabetes FQHC

NCT07417865
View directory record Official record
Conditions
Diabetes
Interventions
ECHO Diabetes tele-education
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 1, 2026, 1:21 AM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics

NCT01013766
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1362885
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Phoenix, Arizona • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Randomized Trial to Evaluate the Effectiveness of Nurse Case Management

NCT00295256
View directory record Official record
Conditions
Type 2 Diabetes, Gestational Diabetes, Hypertension, Preterm Delivery
Interventions
nurse case manager
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Nov 1, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional

Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being

NCT07536256
View directory record Official record
Conditions
Chronic Disease, Adolescent Asthma, Obesity & Overweight, Youth Mental Health, Youth Obesity, Prediabetes, Asthma
Interventions
Community Referral to Kaiona Programs
Behavioral
Lead sponsor
Waianae Coast Comprehensive Health Center
Other
Eligibility
12 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Waianae, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

NCT00924053
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
EGT0001474, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Nov 1, 2026, 1:21 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

NCT03520153
View directory record Official record
Conditions
McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
Interventions
Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

NCT00713830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Nov 1, 2026, 1:21 AM EDT
Completed No phase listed Observational

Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry)

NCT04336800
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Interventions
LiverMultiscan
Device
Lead sponsor
Perspectum
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

Treatment of Peripheral Neuropathy in Patients With Diabetes

NCT00044421
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Irvine, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01068678
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Northridge, California • Palm Springs, California • Paramount, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers

NCT02185729
View directory record Official record
Conditions
Diseases, Metabolic, Insulin Sensitivity
Interventions
Intralipid, ClinOleic, Dextrose, Saline (control)
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Nov 1, 2026, 1:21 AM EDT
Completed No phase listed Observational Results available

Evaluation of VLER-Indiana Health Information Exchange Demonstration Project

NCT01446705
View directory record Official record
Conditions
Diabetes Mellitus, Asthma, Cardiovascular Diseases, Heart Failure, Osteoporosis
Interventions
Active Health Information Exchange, Non-Active Health Information exchange
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
57,073 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Nov 1, 2026, 1:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin Supplementation After Bariatric Surgery

NCT02686905
View directory record Official record
Conditions
Complications of Bariatric Procedures, Avitaminosis
Interventions
Chewable Multivitamin with Iron, PatchMD Vitamin D3/Calcium Patch, PatchMD Multivitamin Patch, PatchMD B12 Energy Plus Patch, Chewable Calcium, Quick Dissolve B12
Dietary Supplement
Lead sponsor
California State Polytechnic University, Pomona
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Brea, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Nov 1, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

NCT05353322
View directory record Official record
Conditions
Sedentary Behavior, Cardiometabolic Risk Factors, Blood Pressure, Glucose
Interventions
Sedentary Break (Walking) Condition, Sitting (Control) Condition, Controlled Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

NCT01819129
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, Insulin aspart, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
77
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Nov 1, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional

Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes

NCT06967701
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Latent Autoimmune Diabetes in Adult (LADA), Pancreatitis
Interventions
Exercise program, Self-monitoring
Behavioral
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Exercise Dose-Response on Features of the Metabolic Syndrome

NCT00687128
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome, Obesity
Interventions
Low-intensity treadmill exercise, Moderate-intensity treadmill exercise, Non-aerobic stretching exercise
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Nov 1, 2026, 1:21 AM EDT
Recruiting Phase 1 Interventional

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

NCT07868354
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Tirzepatide, Zenagamtide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 1, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents

NCT07223151
View directory record Official record
Conditions
Obesity, Adolescent, Dietary Sugars, Taste Perception, Insulin Resistance, Feeding Behavior
Interventions
Unsweetened Sparkling Water Replacement, Progressively Reduced Sugar Beverage Replacement, Plain Water Replacement
Behavioral
Lead sponsor
Nana Gletsu Miller
Other
Eligibility
12 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Bloomington, Indiana • Indianapolis, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

NCT03199053
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Protein and Insulin Sensitivity Study

NCT00508937
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Metabolic Syndrome, Cardiovascular Disease, Dyslipidemia
Interventions
Diet
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Nov 1, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

The Influence of Time-Restricted Eating in Patients With Metabolic Syndrome

NCT04057339
View directory record Official record
Conditions
Metabolic Syndrome, Pre-Diabetes
Interventions
Time Restricted Eating + Standard of Care, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 1, 2026, 1:21 AM EDT